Sickle cell disease has a wide variety of ocular manifestations, of which vaso-occlusive
proliferative retinopathy is the main source of visual morbidity.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Advances in Ophthalmology and OptometryAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Sickle cell disease and the eye: old and new concepts.Surv Ophthalmol. 2010; 55: 359-377
- Sickle-cell disease.Lancet. 2010; 376: 2018-2031
- Sickle cell disease: a distinction of two most frequent genotypes (HbSS and HbSC).PLoS One. 2020; 15: e0228399
- Global epidemiology of haemoglobin disorders and derived service indicators.Bull World Health Organ. 2008; 86: 480-487
- Orbital infarction in sickle cell disease.Am J Ophthalmol. 2008; 146: 595-601
- Orbital complications of sickle cell disease.Int J Pediatr Otorhinolaryngol. 1990; 19: 181-184
- Retrobulbar ischemic optic neuropathy associated with sickle cell disease.J Neuroophthalmol. 1994; 14: 45-48
- The conjunctival sign of sickle-cell disease. Further observations.Arch Ophthalmol. 1962; 68: 627-632
- Iris atrophy in sickle cell disease.Br J Ophthalmol. 1986; 70: 516-521
- Rubeosis iridis and glaucoma associated with sickle cell retinopathy: a light and electron microscopic study.Ophthalmology. 1978; 85: 1028-1041
- Neovascular glaucoma secondary to sickle cell retinopathy.Am J Ophthalmol. 1992; 113: 718-719
- Sickled erythrocytes, hyphema, and secondary glaucoma: I. The diagnosis and treatment of sickled erythrocytes in human hyphemas.Ophthalmic Surg. 1979; 10: 17-31
- Vitreous hemorrhage and retinopathy associated with sickle cell disease.Am J Ophthalmol. 1954; 38: 204-209
- Optic disk neovascularization in hemo- globin SC disease.Am J Ophthalmol. 1978; 85: 711-714
- Foveal avascular zone diameter and sickle cell disease.Arch Ophthalmol. 1991; 109: 812-815
- Paracentral acute middle maculopathy in sickle cell disease.JAMA Ophthalmol. 2015; 133: 614-616
- Ocular findings in elderly cases of homozygous sickle cell disease in Jamaica.Br J Ophthalmol. 1976; 60: 361-364
- Sickle-cell hemoglobin and its relation to fundus abnormality.Arch Ophthalmol. 1966; 75: 353-362
- The evolution of salmon-patch hemorrhages in sickle cell retinopathy.Arch Ophthalmol. 1989; 107: 1814-1815
- Effects of sickle cell disease on the eye: clinical features and treatment.Hematol Oncol Clin North Am. 2005; 19 (ix): 957-973
- Ocular manifestations of sickle hemoglobinopathies.Surv Ophthalmol. 1977; 21: 391-411
- Natural history of untreated proliferative sickle retinopathy.Arch Ophthalmol. 1971; 85: 428-437
- Sickle cell retinopathy: diagnosis and treatment.Arq Bras Oftalmol. 2013; 76: 320-327
- Optical coherence tomography demonstration of macular infarction in sickle cell retinopathy.Arch Ophthalmol. 2006; 124: 746
- Temporal macular thinning on spectral-domain optical coherence tomography in proliferative sickle cell retinopathy.Arch Ophthalmol. 2011; 129: 247
- Structural and functional correlation in sickle cell retinopathy using spectral-domain optical coherence tomography and scanning laser ophthalmoscope microperimetry.Am J Ophthalmol. 2011; 152: 704-711.e2
- Central macular splaying and outer retinal thinning in asymptomatic sickle cell patients by spectral-domain optical coherence tomography.Am J Ophthalmol. 2011; 151: 990-994.e1
- Spectral domain optical coherence tomography in patients with sickle cell disease.Br J Ophthalmol. 2015; 99: 967-972
- Funduscopic examination and SD-OCT in detecting sickle cell retinopathy among pediatric patients.J AAPOS. 2018; 22: 197-201.e1
- Paracentral acute middle maculopathy: precursor to macular thinning in sickle cell retinopathy.BMJ Case Rep. 2017; (bcr-2016-216124)
- Sickle cell retinopathy: what we now understand using optical coherence tomography angiography. A systematic review.Blood Rev. 2019; 35: 32-42
- Analysis of the foveal microvasculature in sickle cell disease using swept-source optical coherence tomography angiography.Sci Rep. 2020; 10: 11795
- Computer-aided classification of sickle cell retinopathy using quantitative features in optical coherence tomography angiography.Biomed Opt Express. 2017; 8: 4206
- Optical coherence tomography angiography and ultra-widefield fluorescein angiography for early detection of adolescent sickle retinopathy.Am J Ophthalmol. 2017; 183: 91-98
- Detection and monitoring of sickle cell retinopathy using ultra wide-field color photography and fluorescein angiography.Retina. 2011; 31: 738-747
- New ways to detect pediatric sickle cell retinopathy: a comprehensive review.J Pediatr Hematol Oncol. 2017; 39: 618-625
- Correlation of multimodal imaging in sickle cell retinopathy.Retina. 2016; 36: S111-S117
- Incidence and natural history of proliferative sickle cell retinopathy: observations from a cohort study.Ophthalmology. 2005; 112: 1869-1875
- A screening strategy for the detection of sickle cell retinopathy in pediatric patients.Can J Ophthalmol. 2008; 43: 188-191
- Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.JAMA. 2014; 312: 1033
- New classification of peripheral retinal vascular changes in sickle cell disease.Br J Ophthalmol. 1994; 78: 681-689
- Laser therapy for retinopathy in sickle cell disease.in: Myint K.T. Cochrane database of systematic reviews. John Wiley & Sons, Ltd, 2015: 9-14
- Laser photocoagulation for proliferative retinopathy in sickle haemoglobin C disease.EYE. 1993; 7: 703-706
- Retinal photocoagulation for proliferative sickle cell retinopathy: a prospective clinical trial with new sea fan classification.Eur J Ophthalmol. 2008; 18: 248-254
- An update on techniques of photocoagulation treatment of proliferative sickle cell retinopathy.Eye. 1991; 5: 260-263
- Cryotherapy of proliferative sickle retinopathy, II: triple freeze-thaw cycle.Br J Ophthalmol. 1979; 63: 97-101
- Photocoagulation and diathermy in the treatment of proliferative sickle retinopathy.Br J Ophthalmol. 1974; 58: 650-662
- A randomized clinical trial of scatter photocoagulation of proliferative sickle cell retinopathy.Arch Ophthalmol. 1991; 109: 363-367
- A randomized clinical trial of feeder vessel photocoagulation of sickle cell retinopathy. A long-term follow-up.Ophthalmology. 1991; 98: 581-585
- Trans-scleral diode laser photocoagulation in proliferative sickle cell retinopathy.Ophthalmology. 1999; 106: 1828-1829
- Expression pattern of HIF-1α and VEGF supports circumferential application of scatter laser for proliferative sickle retinopathy.Investig Ophthalmol Vis Sci. 2016; 57: 6739-6746
- Retinal breaks after photocoagulation of proliferative sickle cell retinopathy.Arch Ophthalmol. 1980; 98: 676-679
- Expression of the angiogenic mediator, angiopoietin-like 4, in the eyes of patients with proliferative sickle retinopathy.PLoS One. 2017; 12: e0183320
- Expression of pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor (VEGF) in sickle cell retina and choroid.Exp Eye Res. 2003; 77: 433-445
- Increased circulating PEDF and low sICAM-1 are associated with sickle cell retinopathy, blood cells.Mol Dis. 2015; 54: 33-37
- Angiogenic factors in human proliferative sickle cell retinopathy.Br J Ophthalmol. 1999; 83: 838-846
- Intravitreal bevacizumab (Avastin) injection associated with regression of retinal neovascularization caused by sickle cell retinopathy [7.Acta Ophthalmol Scand. 2006; 84: 834-835
- Intravitreal ranibizumab for stage IV proliferative sickle cell retinopathy: a first case report.Case Rep Ophthalmol Med. 2014; 2014: 682583
- Variable practice patterns for management of sickle cell retinopathy.Ophthalmol Retina. 2020; https://doi.org/10.1016/j.oret.2020.11.017
- Intravitreal bevacizumab (Avastin) for the treatment of proliferative sickle retinopathy.Indian J Ophthalmol. 2008; 56: 259
- Intravitreal bevacizumab for proliferative sickle retinopathy: a case series.J Vitreoretin Dis. 2018; 2: 32-38
- Bevacizumab presurgical treatment for proliferative sickle-cell retinopathy-related retinal detachment.Retin Cases Brief Rep. 2013; 7: 204-205
- Intravitreal bevacizumab (Avastin) associated with secondary hyphaema in a case of proliferative sickle cell retinopathy.BMJ Case Rep. 2010; 2010 (bcr1120092441)
- Surgical and medical perioperative management of sickle cell retinopathy: a literature review.Int Ophthalmol Clin. 2020; 60: 77-87
- An update on vitrectomy surgery and retinal detachment repair in sickle cell disease.Arch Ophthalmol. 1982; 100: 591-593
- Pars plana vitrectomy in the management of complications of proliferative sickle retinopathy.Arch Ophthalmol. 1988; 106: 1553-1557
- Vitreoretinal management of the complications of sickle cell retinopathy by observation or pars plana vitrectomy.Eye. 2009; 23: 1314-1320
- Vitreoretinal management and surgical outcomes in proliferative sickle retinopathy: a case series.Am J Ophthalmol. 2014; 157: 870-875.e1
- A comparison of 23-gauge and 20-gauge vitrectomy for proliferative sickle cell retinopathy - clinical outcomes and surgical management.Eye. 2018; 32: 1449-1454
Article info
Publication history
Published online: June 04, 2021
Identification
Copyright
© 2021 Elsevier Inc. All rights reserved.
